Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
Date:6/15/2010

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of the drugs in Isis' pipeline.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2009 and its most recent quarterly report on Form 10-Q, which are on file with the SEC.  Copies of these and other documents are available from the Company.  

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc.

Isis Pharmaceuticals is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics is a trademark of Regulus Therapeutics Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Texas (PRWEB) May 24, 2013 ... benchmarking survey on kinase profiling carried out in ... details of the breakdown of the responses for ... the future (2015). It also highlights some interesting ... survey groupings. Two bottom-up models were developed to ...
(Date:5/24/2013)... Many factors impact tissues targeting such as protein ... the blood-tissue barrier. Even when tissue disposition is achieved, ... tissue rather than the total tissue concentration. , A ... guide lead optimization, predict in vivo activity in animal ... impact the likely human clinical dose. , In this ...
(Date:5/24/2013)... City, OK (PRWEB) May 24, 2013 The ... of casualties. And following its ravage, the mayor of Moore, ... bill for new houses, said a report from cnn.com. Reaching ... the tornado victims complimentary Molderizer and Safe Shield to counter ... to the report published on May 22, 2013, caused 24 ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly traded ... development, sales and marketing of premium branded highly ... it is awarding exclusive Vestiage territories in the ... Illuminating Facial Care. Qualified applicants can request an ... to info(at)vestiageinc(dot)com and putting RELUMA in the "Subject" ...
Breaking Biology Technology:Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5
... how big a software project was, and we will often ... have units of time. How big was another 11,000-hour project ... 11,000-hour project that produced only a little bitof software, but ... software size, but without a measurable ounce of software, we're ...
... is the 10th in a series of articles on developing ... , Madison, Wis. - In Step 9 ... we focus specifically on the federal laws. , ,Any ... state and federal securities laws and regulations. Of equal importance ...
... adoption of healthcare information technology continues its slow but steady march, ... ,The progress that has been made, and the issues still to ... Conference set for May 9 and 10 at the Fluno ... , Dr. Barry Chaiken Dr. Barry Chaiken, associate chief ...
Cached Biology Technology:Defining the X-factor: What is an ounce of software worth? 2Defining the X-factor: What is an ounce of software worth? 3Defining the X-factor: What is an ounce of software worth? 4Early Stage 10: The nuances of federal laws 2Early Stage 10: The nuances of federal laws 3Early Stage 10: The nuances of federal laws 4Early Stage 10: The nuances of federal laws 5Digital Healthcare Conference 2007: Mounting obstacles for health IT 2Digital Healthcare Conference 2007: Mounting obstacles for health IT 3
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) ... among grasses , Within the genome of each ... undergo little change in position and sequence over millions ... Some of these evolutionarily stable sequences, so-called conserved noncoding ... other genes or the condensation of chromosomes, but the ...
(Date:5/23/2013)... most popular fruit, can be made both better-tasting and ... , "Working with GM tomatoes that are different ... specific compound, allows us to pinpoint exactly how to ... the John Innes Centre. , The research could also ... shelf life characteristics because even higher levels of the ...
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than 165 ... intellectual property at PNNL,s annual Intellectual Property Commercialization ... Department of Energy national laboratory named materials scientist ... work developing battery materials that can store large ... grid, and reduce the time it takes to ...
Breaking Biology News(10 mins):Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3The world's favorite fruit only better-tasting and longer-lasting 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
... SALT LAKE CITYLeukemia is the most common childhood cancer; ... zebrafish at Huntsman Cancer Institute (HCI) at the University ... in T-cell acute lymphocytic leukemia (T-ALL), according to an ... research journal Oncogene . When compared to samples ...
... Boys and girls have put many of the trappings of teenagerhood ... least some of the brain resculpting that characterizes the decade of ... findings in a new study that measured brainwaves of subjects in ... the kinds of neurological changes underway in a teen brain is ...
... at Washington State University Spokane offers hope to those ... which was published online this week in the journal ... nerve damage incurred during childhood can improve with intensive ... there isn,t just a one-year window for facial rehabilitation, ...
Cached Biology News:Zebrafish models identify high-risk genetic features in leukemia patients 2Study: Pace of brain development still strong in late teens 2WSU study expands time window for facial nerve rehabilitation 2
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
This kit is designed to select cells labeled with biotinylated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
This pump accomodates StemSep ; pump feed columns of the following sizes : 0.3in., 0.5in., 0.6in., and 1.0in.....
... assays. The TUNEL-based assay kit provides complete ... for convenient detection of DNA fragmentation in ... offers an one-step labeling of apoptotic cells. ... hallmark of apoptosis in mammalian cells. MBLs ...
Biology Products: